Stacy Remiszewski, PhD

Adjunct Professor of Drug Discovery and Development

Training:

BA: Rutgers University, research advisor Hugh W. Thompson

PhD: The Pennsylvania State University, thesis advisor Steven M. Weinreb

Post-doctoral Reseach: The University of Pennsylvania, research advisor Amos B. Smith, III

Research Overview:

Stacy received his PhD in Synthetic Organic Chemistry completing the total synthesis two aminosugars using N-sulfinyl Diels-Alder chemistry. While at Penn State he also developed methodology for enantioselective N-sulfinyl Diels-Alder reactions. Stacy moved to the University of Pennsylvania where he expanded his experience in synthetic organic chemistry contributing to the total synthesis of (+)-Latrunculin A.

After completing his post-doctoral research project, Stacy moved to Schering-Plough Pharmaceuticals where he began his career as a medicinal chemist specializing in oncology research. While at Schering, Stacy worked on developing inhibitors of Ras nucleotide exchange and Ras farnesyl transferase inhibitors where his contribution led to him winning the Schering-Plough President’s Award for Discovery of Sarasar (SCH66336). He moved to Novartis Pharmaceuticals where he led the efforts on the oncology project to inhibit Class I and II histone deacetylases. His efforts resulted in entering two compounds into Phase I clinical trials in five years, one of which, the drug Farydak^®, has been approved as a multiple myeloma treatment. These efforts resulted in Stacy being awarded the Novartis Leading Scientist Award for Discovery of Panobinostat (NVP-LBH589).

Stacy then moved to Hofmann-La Roche as Director, Section Head of Oncology Chemistry. While at Roche, he oversaw MEK, CDK, BCL2, and MDM2 inhibitors projects. His most significant contribution at Roche was leading the team that discovered selective XIAP Bir2 antagonists as a novel approach to cancer therapy.

Stacy is currently Vice President of Research at Evrys Bio focused on identifying novel host-targeted antivirals targeting the protein SIRT2. He leads efforts in medicinal chemistry, in vitro and in vivo biology, pharmacokinetics, ADMET and translational research.

Research Projects:

SIRT2 modulation as a novel host-targeted approach to broad spectrum antiviral drug discovery.
Benzazepinones and Benzoxazepinones as BIR2-Selective XIAP Inhibitors.
Inhibiting the kinases MEK and CDK as anticancer therapeutics.
Inhibiting protein-protein interactions as a novel method of treating solid tumors.
Inhibiting Class I and II histone deacetylases as a mechanism to treat solid and liquid tumors.
Ras nucleotide exchange inhibitors and farnesyl transferase inhibition to affect tumor growth.
Total synthesis of natural products and hetero-Diels-Alder chemistry.

Publications

“An allosteric inhibitor of sirtuin 2 blocks hepatitis B virus covalently closed circular DNA establishment and its transcriptional activity” Tang, L., Remiszewsk,i S., Snedeker, A., Chiang, L.W., Shenk, T. Antiviral Res 2024 Jun;226:105888. doi: 10.1016/j.antiviral.2024.105888.
“Inhibition of SIRT2 promotes death of human cytomegalovirus-infected peripheral blood monocytes via apoptosis and necroptosis” Cheung, J.; Remiszewski, S.; Chiang L.W.; et al. Antiviral Res 2023 Sep:217:105698. doi: 10.1016/j.antiviral.2023.105698.
“An allosteric inhibitor of sirtuin 2 deacetylase activity exhibits broad-spectrum antiviral activity” Roche , K.L.; Remiszewski, S.; Todd, M.J.; et al. J Clin Invest. 2023;133(12):e158978
“Benzazepinones and Benzoxazepinones as BIR2-Selective XIAP Inhibitors” Donnell, A. F.; Michoud, C.; Rupert, K.; Han, X.; Aguilar, D.; Remiszewski, S. W.; et al. J. Med. Chem. 2013, 56, 7772.
“Optimization of Benzodiazepinones as Selective Inhibitors of XIAP BIR2 Domain” Kester, R. F.; Donnell, A. F.; Lou, Y.; Remiszewski, S. W.; et al. J. Med. Chem. 2013, 56, 7778.